Recombinant L-IFN adenovirus injection

DRUG2 trials

Sponsors

Shanghai Fengxian District Central Hospital, Binhai Hospital of Fujian Medical University

Conditions

Bladder CancerBreast CancerCervical CarcinomaHead and Neck CancerLung CancerMelanomaOvarian CarcinomaRecurring Glioblastoma

Early Phase 1

Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study

Shanghai Fengxian District Central HospitalBladder Cancer, Breast Cancer, Cervical Carcinoma +4

Start: 2021-11-30End: 2023-12-31Target: 28Updated: 2022-02-01

Safety and Tolerability Study of Recombinant L-IFN Adenovirus Injection in Patients With Recurrent Glioblastoma

Binhai Hospital of Fujian Medical UniversityRecurring Glioblastoma

Start: 2023-06-27End: 2024-12-30Target: 6Updated: 2023-06-28

Related Papers

An investigator-initiated trial to evaluate safety and tolerability of YSCH-01 in patients with recurrent glioblastoma.

Journal of Clinical Oncology2024-08-101 citations

Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial

Journal for ImmunoTherapy of Cancer2024-05-0112 citations